Ruxolitinib Adverse Event Data and Strategies for Managing Side EffectsApril 7th 2022
Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.
Introduction: A 58-Year-Old Man With Moderate Steroid-Refractory cGVHD and Risk Factors for cGVHDApril 7th 2022
Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.
Addition of Lenalidomide to SOC Shows Feasibility, Safety in MDS, AML and CMMLApril 3rd 2022
AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.
Use of Cyclophosphamide GVHD Prophylaxis, Prior Cardiac Disease May Increase Cardiac Toxicity After AlloHCTMarch 24th 2022
Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.
CARCIK-CD19 Protocol Provides Lymphodepleted Patients Access to CAR T-cell Treatment in B-ALLMarch 24th 2022
Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.
Maribavir Demonstrates Positive Safety Results Compared to Investigator-Assigned Therapy in Transplant RecipientsMarch 23rd 2022
Lower rates of neutropenia and hypokalemia were also observed with maribavir than valganciclovir, ganciclovir, and foscarnet, and a lower proportion of HCT recipients discontinued treatment with maribavir than IAT.
Feasibility of Using Haploidentical Donors for alloHCT Shown in Patients With Ph+ CMLMarch 23rd 2022
Haploidentical donor-derived allogeneic hematopoietic cell transplant appears to be feasible for patients with Philadelphia chromosome-positive chronic myeloid leukemia, similar to other donor types.